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Abstract
Background: A reanalysis of the ALBIOS trial suggested that patients with septic shock - defined by vasopressor-
dependent hypotension in the presence of severe sepsis (Shock-2) - had a survival benefit when treated with
albumin. The new septic shock definition (Shock-3) added the criterion of a lactate threshold of 2 mmol/L. We
investigated how the populations defined according to Shock-2 and Shock-3 differed and whether the albumin
benefit would be confirmed.
Methods: This is a retrospective analysis of the ALBIOS study, a randomized controlled study conducted between
2008 and 2012 in 100 intensive care units in Italy comparing the administration of 20% albumin and crystalloids
versus crystalloids alone in patients with severe sepsis or septic shock. We analyzed data from 1741 patients from
ALBIOS with serum lactate measurement available at baseline. We compared group size, physiological variables and
90-day mortality between patients defined by Shock-2 and Shock-3 and between the albumin and crystalloid
treatment groups.
Results: We compared the Shock-2 and the Shock-3 definitions and the albumin and crystalloid treatment groups
in terms of group size and physiological, laboratory and outcome variables. The Shock-3 definition reduced the
population with shock by 34%. The Shock-3 group had higher lactate (p < 0.001), greater resuscitation-fluid
requirement (p = 0.014), higher Simplified Acute Physiology Score II (p < 0.001) and Sepsis-related Organ Failure
Assessment scores (p = 0.022), lower platelet count (p = 0.002) and higher 90-day mortality (46.7% vs 51.9%; p = 0.031).
Albumin decreased mortality in Shock-2 patients compared to crystalloids (43.5% vs 49.9%; 12.6% relative risk reduction;
p = 0.04). In patients defined by Shock-3 a similar benefit was observed for albumin with a 11.3% relative risk reduction
(48.7% vs 54.9%; 11.3% relative risk reduction; p = 0.22).
Conclusions: The Sepsis-3 definition reduced the size of the population with shock and showed a similar effect size in
the benefits of albumin. The Shock-3 criteria will markedly slow patients’ recruitment rates, in view of testing albumin
in septic shock.
Trial registration: ClinicalTrials.gov, number NCT00707122. Registered on 30 June 2008.
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Background
Septic shock is a major challenge in intensive care and its
treatment remains elusive despite decades of basic, trans-
lational and clinical research. Given that sepsis is a syn-
drome rather than a disease, the individual response to
treatment may be heavily confounded by its underlying
etiology and pathophysiologic phenotype, which represent
an unavoidable source of heterogeneity in patients with
sepsis. An additional source of heterogeneity however, de-
rives from the severity of sepsis. Indeed, various clinical
definitions of septic shock identify patients with different
severity and mortality risk, depending on the criteria they
employ. Historically, at the beginning of the randomized
clinical studies era, the inclusion criteria were mainly
based on the authors’ initiative. Therefore, efforts have
been made to select criteria that identify a more homoge-
neous subset of septic patients with a greater mortality
risk than the one associated to sepsis alone. A consensus
conference in 1991 defined septic shock as “sepsis-in-
duced hypotension [persisting] despite adequate fluid
resuscitation”, which could be further categorized as
cardiovascular Sepsis-related Organ Failure Assessment
(SOFA) score of 1, 3 or 4 [1–3]. However, the applica-
tion of similar criteria led to the enrollment of remark-
ably different populations into clinical trials in different
countries, with striking differences in mortality rates
[4]. In Italy, the ALBIOS study had an overall 90-day
mortality rate of 42.2% [1], similar to the one recorded
in Scandinavia (44%) [5] and in France (43%) [6]. How-
ever, the mortality was remarkably lower in trials con-
ducted in the USA (32%) [7] or in Australia and New
Zealand (18.8%) [8]. These trials highlighted the fact
that the “Sepsis 2” criteria for septic shock were inad-
equate to identify patients with comparable severity
and raised the issue of the results of these trials not
being generalizable to the “real world” population (i.e.,
external validity). In 2016, a new consensus definition -
in an effort to increase predictive validity - proposed
the need for both vasopressor-dependent hypotension
and serum lactate greater than 2 mmol/L after adequate
fluid resuscitation to define septic shock (Shock-3
definition) [9]. Indeed, the association between serum
lactate levels and mortality is one of the oldest and
most consistent relationship in intensive care and its
inclusion in the definition of shock is based on the clear
correlation between excess lactate level and severity of
illness, the lactate level being a crude surrogate for
cellular and metabolic abnormalities [10].
In this study, we reanalyzed the results from the
ALBIOS study [1] - which in 2014 compared the efficacy
of the administration of albumin and crystalloids versus
crystalloids alone in patients with septic shock - based on
the new definition of septic shock. Our aim was to report
differences in the populations classified as Shock-2 or
Shock-3, highlighting possible advantages and disadvan-
tages of this new definition.
Methods
This study was a retrospective analysis of data from the
ALBIOS study [1]. ALBIOS was a multicenter random-
ized controlled trial (RCT) conducted between 2008 and
2012 in 100 Italian intensive care units, comparing the
administration of 20% albumin and crystalloids versus
crystalloids alone from randomization to day 28 or dis-
charge from ICU (whatever came first), in the treatment
of 1818 adult patients with severe sepsis or septic shock
(eligibility criteria available in the online supplement of
the ALBIOS trial [1]). In Table 1, we summarize the
criteria we used for the septic shock definition in the
ALBIOS study and the one used in the present study. As
shown, the differences were related to the availability of
lactate levels at baseline and the lactate threshold.
Accordingly, we compared the patient subpopulations
defined on the basis of Shock-2 (1098 patients) and
Shock-3 (721 patients) criteria in terms of physiological,
gas exchange, hemodynamic and outcome variables.
Statistical analysis
All the analyses were conducted on an intention-to-treat
basis. Binary outcomes were compared with the use of
the chi-square test and continuous outcomes with the
use of the Wilcoxon rank-sum test. Results were re-
ported as mean plus or minus standard deviation, as ap-
propriate. Survival estimates were calculated according
to the Kaplan–Meier method and compared using the
log-rank test, stratified for Sepsis-2 and Sepsis-3 defini-
tions, to compare the albumin and crystalloid treat-
ments. p values < 0.05 were considered significant. We
performed all analyses with R software.
Results
In Fig. 1, we show the mortality rate as a function of
baseline serum lactate level recorded in patients with
severe sepsis with (Septic shock, n = 1098) or without
Table 1 Patient population
Entry criteria Septic shock
ALBIOS
Shock-2 present
study
Shock-3
present study
Severe sepsis +
cardiovascular
Sepsis-related
Organ Failure
Assessment
score 3 or 4
As septic shock
ALBIOS, in which
baseline lactate
was available
Shock-2 patients
with baseline
lactate > 2 mmol/L
Patients n 1135 1098 721
Patients lost
at follow up
n 14 12 8
Mortality data
available
n 1121 1086 713
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shock (Severe sepsis, n = 643) according to the ALBIOS
definition. As shown, mortality increased with increasing
baseline lactate, both in patients with septic shock (p <
0.0001) and in patients with severe sepsis without shock
(p = 0.008). In the same figure, we show the Shock-3
population, which includes only patients with baseline
serum lactate above 2 mmol/L. As shown, 377 patients
(34%) previously classified as having septic shock, no
longer met the criteria for shock - based on the lactate
criterion (Shock-3 definition). The change in the inclu-
sion criteria increased the group of patients with severe
sepsis without shock from 643 to 1020 patients. In Fig. 2a
we show the probability of survival according to the
Sepsis-2 and Sepsis-3 definitions. Of note, at 90 days,
survival was significantly lower in the subgroup of pa-
tients with septic shock and higher lactate (Shock-3)
than in patients with shock that had been defined ac-
cording to Sepsis 2 criteria (Shock-2) independent from
the lactate level (chi-square test p = 0.031).
Patients with septic shock
In Table 2, we compare several baseline physiological
and clinical variables recorded following the Shock-2
versus Shock-3 definition. The application of the new
classification decreased the population with septic shock
by about 34% and increased its severity. Indeed, besides
the higher serum lactate levels dictated by the definition
criteria, patients defined by Shock-3 had a significantly
higher mortality rate (absolute mortality difference of 5.2%),
higher SOFA scores and higher Simplified Acute Physiology
(SAPS)-II scores. In addition, they had a significantly lower
platelet count, a more positive fluid balance at 6 h
and received a larger amount of fluid resuscitation in
the first 24 h.
Patients without shock
The reclassification of 377 patients from the “septic
shock” to the “severe sepsis without shock” group in-
creased the size of the latter by nearly 60%. Besides the
differences linked to the new criteria (e.g., all 377
patients transferred had, by definition, norepinephrine
infusion), all the other statistically significant differences
that we found do not appear clinically relevant (mean ar-
terial pressure difference 2 mmHg, central venous pres-
sure difference 0.5 mmHg, lactate difference 0.5 mmol/L
and pH difference 0.01, results not shown). Mortality
was also similar between the subgroup of patients with
sepsis based on the Sepsis-2 and Sepsis-3 definitions
(34.7% vs 35.5%).
Sepsis and albumin
The results of the ALBIOS study indicated that the use
of albumin in addition to crystalloids, as compared with
the use of crystalloids alone, in patients with severe sep-
sis or septic shock during their stay in the ICU did not
provide a survival benefit at 90 days, despite improve-
ments in hemodynamic variables.
Patients defined by Shock-2
In Fig. 2a, b, we compare the survival probability of
patients defined by Shock-2 and Shock-3 relative to
patients defined by Sepsis-2 and Sepsis-3. As shown, in
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Fig. 1 Mortality according to baseline lactate levels in patients with severe sepsis (light bars) or septic shock (dark bars). Chi-square test: sepsis,
p = 0.008; septic shock, p < 0.0001
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both cases, survival was significantly higher in patients
with sepsis compared to patients with shock. In Fig. 2c,
we compare the effect of albumin versus crystalloids in
patients defined by Shock-2 and Shock-3. As shown, in
the population defined by Shock-2, the mean survival
days are not significantly different between albumin and
control treated patients (log rank test p = 0.08); however,
the absolute mortality rate at 90 days is significantly dif-
ferent (43.5% vs 49.9%, absolute risk reduction 6.3%, risk
ratio 0.89, 95% CI 0.79–0.99, Chi-square test p = 0.04).
In patients defined by Shock-3, the mortality rate was
48.7% in the albumin group and 54.9% in the control
group (absolute risk reduction 6.2%, risk ratio 0.88, 95%
CI 0.75–1.02). The mortality difference, however, was
not statistically significant (p = 0.11), nor was the mean
number of survival days (p = 0.246).
Discussion
The main finding of our study was that Shock-3 criteria
applied to the ALBIOS population selected a smaller but
more severely ill population affected by higher mortal-
ity. The relative risk reduction in mortality observed in
septic patients defined by Shock-2 and treated with al-
bumin, compared to those treated with crystalloids,
remained similar when applying the Sepsis-3 criteria
(i.e., lactate > 2 mmol/L) (12.6% vs 11.3%) but was no
longer significant, due to the smaller size of the septic
shock group. The relative risk reduction from 12.6 to
11.3% suggests that the proposed effect of albumin, if
any, does not depend on lactate level and the shock
definition. The introduction of the Sepsis-3 definition
of septic shock opens a new scenario concerning the
reanalysis of previous RCTs and the design of future tri-
als. On the wave of the enthusiasm for the new definition,
some authors - like Russell et al. [11] and ourselves - will
reanalyze previous RCT data under the light of the new
classification of septic shock, either confirming the previ-
ous findings or reporting new ones. Regardless of their
results, these studies will probably be considered as a new
discovery, as they will be obtained from randomized trials
Fig. 2 Probability of survival from randomization to day 90. a Kaplan–Meier estimates for the probability of survival among patients classified by
Sepsis-2 versus Shock-2. Mean survival time 66.7 (95% CI 64.1–69.2) vs 56.4 (95% CI54.1–58.7) days. Log rank test p < 0.001. Absolute 90-day
mortality 34.1% vs 46.7%, respectively. Chi-square test p < 0.001. b Kaplan–Meier estimates of Sepsis-3 vs Shock-3. Mean survival time 66.3 (95% CI
64.2–68.4) vs 51.6 (95% CI 48.7–54.5) days. Log rank test p < 0.001. Absolute 90-day mortality 35.0% vs 51.9%, respectively. Chi-square p < 0.001). c
Kaplan–Meier estimates for the probability of survival in patients defined by Shock-2, treated with albumin versus crystalloids. Mean survival time
57.9 (95% CI 54.7–61.1) vs 54.9 (95% CI 51.7–58.2). Log rank test p = 0.082. Absolute 90-day mortality 43.5% vs 49.9% (absolute risk reduction 6.3%,
risk ratio 0.89, 95% CI 0.79–0.99). Chi-square test p = 0.04. d Kaplan–Meier estimates for the probability of survival in patients defined by Shock-3,
treated with albumin versus crystalloids. Mean survival time: 52.9 (95% CI 48.6–57.1) vs 50.4 (95% CI 46.4–54.4). Log rank test p = 0.246. Absolute
90-day mortality 48.7% vs 54.9% (absolute risk reduction 6.2%, risk ratio 0.88, 95% CI 0.75–1.02). Chi-square test p = 0.11
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conducted by authoritative experts who provided the new
septic shock definition. Indeed, the reanalysis by Russell et
al. showed that vasopressin was only effective in less
severely ill patients (with lactate ≤ 2 mmol/L; i.e., sepsis
according to the new definition) - with an absolute
risk reduction of 12.3% (hazard ratio (HR) 0.67; 95%
CI 0.46–0.96), while it had no benefit in patients with
lactate > 2 mmol/L (absolute risk reduction of 2.%;
HR 0.97; 95% CI 0.74–1.27). In our study we found a
similar relative risk reduction in mortality.
It would not be surprising to find that the effect size
of some of the major RCTs that contributed to guide
clinical practice may lead to different conclusions if sub-
jected to reanalysis with the inclusion criteria of
Sepsis-3. However, we should consider that any reanaly-
sis of a previous trial using the new criteria is no more
than an unplanned, post hoc, subgroup analysis and, as
such, does not possess enough scientific rigor to change
clinical practice.
The goal of the new definition was primarily to in-
crease homogeneity in the severity and risk of death of
patients with septic shock while separating them from
the patients with sepsis with a lower mortality risk.
Undoubtedly, from this perspective, serum lactate
works. Russell et al. analyzing the VASST trial [12]
found an increase in 90-day mortality in patients with
lactate > 2 mmol/L (from 43.9% of the original group
to 55% in patients with the Sepsis-3 definition of sep-
tic shock), which is consistent with the difference in
the mortality risk demonstrated in the validation study
of the Sepsis-3 definition [13]. This new proposed
classification may lead to greater homogeneity in se-
verity and associated risk of death across all studies in
septic shock. This would increase the external validity
Table 2 Patients with septic shock (Shock-2 and Shock-3 definition) treated with albumin or crystalloids
Shock 2
N = 1098
Shock 3
N = 721
Albumin
N = 549
Crystalloids
N = 549
p value Albumin
N = 346
Crystalloids
N = 375
p value
MAP (mmHg) 70.9 ± 14.4 70.8 ± 14.1 0.958a 70.4 ± 14.8 69.0 ± 14.0 0.190a
CVP (mmHg) 10.8 ± 5.0 10.8 ± 4.9 0.877a 11.0 ± 5.1 10.8 ± 4.9 0.583a
HR (bpm) 106.5 ± 22.1 106.8 ± 20.4 0.819a 109.8 ± 21.5 109.2 ± 19.8 0.672a
SvO2 (%) 71.4 ± 11.14 73.3 ± 10.0 0.005
a 70.7 ± 11.9 73.0 ± 10.2 0.007a
PaCO2 (mmHg) 39.2 ± 12.4 39.2 ± 9.7 0.960
a 38.1 ± 11.4 38.67 ± 9.8 0.455
PvCO2 (mmHg) 46.7 ± 12.6 46.3 ± 10.3 0.524
a 45.9 ± 11.8 45.69 ± 10.7 0.833a
Noradrenaline (μg/kg/min) 1.9 ± 0.8 1.3 ± 0.6 0.042a 1.9 ± 0.9 1.3 ± 0.6 0.126a
Patients on noradrenaline 463 (84.3%) 458 (83.4%) 0.682c 296 (85.5%) 321 (85.6%) 0.985c
Lactate (mmol/L) 3.7 ± 3.2 4.1 ± 3.4 0.040b 5.11 ± 3.3 5.31 ± 3.4 0.487b
pH 7.40 ± 0.1 7.4 ± 0.1 0.883a 7.35 ± 0.1 7.34 ± 0.1 0.597a
BE (mmol/L) −3.9 ± 6.1 −3.7 ± 6.2 0.800b −4.8 ± 6.2 −4.6 ± 6.2 0.937b
Albumin (g/L) 23.5 ± 6.3 24.1 ± 6.1 0.138b 23.4 ± 6.4 23.9 ± 6.2 0.617b
Creatinine (mg/dL) 2.2 ± 1.7 2.1 ± 1.5 0.153a 2.3 ± 1.6 2.2 ± 1.5 0.175a
Diuresis (ml/h) 70.6 ± 71.1 72.7 ± 76.5 0.610b 68.8 ± 73.3 69.2 ± 75.7 0.847b
Fluid balance (6 h) (L) 1.2 ± 1.4 1.2 ± 1.7 0.549b 1.4 ± 1.5 1.5 ± 1.8 0.918b
Fluid input (day 1) (L) 4.8 ± 2.3 4.8 ± 2.3 0.917b 5.1 ± 2.4 5.1 ± 2.5 0.710b
SOFA 9.3 ± 2.6 9.4 ± 2.8 0.782b 9.9 ± 2.7 9.9 ± 2.8 0.906b
SAPS II 52.1 ± 17.0 52.7 ± 17.1 0.592a 55.6 ± 17.0 55.8 ± 17.1 0.911a
Mortality (90 day) 237 (43.6%) 270 (49.8%) 0.039c 167 (48.7%) 203 (54.9%) 0.099c
WBC 13.4 ± 10.3 13.2 ± 10.8 0.762a 12.9 ± 11.0 12.6 ± 11.5 0.644a
PLT 176 ± 118 181 ± 131 0.873b 156 ± 109.9 164 ± 126.1 0.592b
Physiological and outcome variables (mean ± standard deviation or number (percentage)) measured at baseline in patients classified according to the criteria for
septic shock adopted in the ALBIOS trial compared to the Shock-3 definition
MAP mean arterial pressure, CVP central venous pressure, HR heart rate, SvO2 central venous saturation, PaCO2 arterial CO2 partial pressure, PvCO2 venous CO2,
partial pressure, BE base excess, SOFA Sepsis-related Organ Failure Assessment, SAPS-II Simplified Acute Physiology Score II, WBC white cell count, PLT
platelet count
aAnalysis of variance for continuous normally distributed variables
bMann–Whitney test for continuous non-normally distributed variables
cChi-square test for discrete variables
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of the trial particularly when the reported crude mor-
tality rates in the control group are as disparate as
18.8% in ARISE [8], 33.7% in ProCESS [7] and up to
56.9% at 60 days in the study by Rivers et al. [14].
However, the selection of a more severely ill popula-
tion may present some drawbacks related to the treat-
ment effect size and the repercussions on power and
population sample size. In our analysis we found that
the introduction of the 2 mmol/L lactate threshold
was associated with an absolute increased risk of 5.2%
(relative increase 11%). This figure roughly indicates
the order of magnitude of the “attributable mortality”
due to the increase in sepsis severity associated with
the threshold of 2 mmol/L. These data may be helpful
in defining the expected changes in mortality in future
trials.
The second issue of the sample size may pose
greater problems of the feasibility of new RCTs. In-
deed, the number of patients required to be enrolled
to show a significant difference in outcome increases
as the baseline mortality approaches 50% and the
length of the study will be greatly prolonged. As an
example, targeting an absolute reduction in mortality
of 6% from a baseline expected mortality of 40%, the
required sample size would be 2030 patients (alpha
0.05 and beta 0.2). As indicated in Table 3, consider-
ing 31 participating centers (median value from previ-
ous RCTs) and a recruitment rate of 0.68 patients/
unit/month (mean value), a study would be completed
in 8 years applying the Sepsis-2 criteria. In contrast,
applying Sepsis-3 criteria - higher mortality (50%) and
30% smaller population - the same study would require
approximately 12 years.
Conclusions
We showed that the Shock-3 definition did not affect
the treatment effect size (12.6–11.3%) and that pos-
sible benefits of albumin were no longer significant.
Shock-3 criteria have the advantage of increasing the
external validity of studies by selecting a population
with more severe sepsis, though not necessarily more
homogeneous. However, it has the disadvantages of
greater difficulty in recruitment, duration and cost of
the trial. Extreme caution must be taken when inter-
preting previous clinical trials designed for Sepsis-2
criteria being reanalyzed using the new definition, as
the finding will have the limitations of a subgroup
analysis and, as such, it should not be considered a
rigorous finding fulfilling the requirements to influ-
ence or change clinical practice.
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Table 3 Enrolment rate of septic shock patients in recent randomized controlled trials on sepsis
Study TRISS [5] SEPSISPAM [6] ProCESS [7] ARISE [8] ALBIOS [1] VASST [12]
Patients enrolled (n) 1005 776 1341 1600 1135 778
Enrollment mid-date 2012 2011 2011 2011 2010 2003
Enrollment period (months) 25 22 74 66 42 57
Centers (n) 32 29 31 51 100 27
Enrollment rate (patients/month/center) 1.26 1.22 0.58 0.24 0.27 0.52
Enrollment rate (patients/month) 40.3 35.4 18 12 27 14
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